However, in contrast to the dose-dependent inhibitory effects of CO-EtOAc on hepatic steatosis, it seems that higher dose of CO-EtOAc did not provide stronger effects on reverting insulin signaling, and the similar phenomenon can also be observed in the blood glucose lowering effects of CO-EtOAc. The gene discussed is INS; the disease is Hepatic steatosis.